Literature DB >> 10631575

Genes, cells and cytokines in resistance against development of toxoplasmic encephalitis.

Y Suzuki1.   

Abstract

Toxplasma gondii is an intracellular protozoan parasite which invades various organs including the central nervous system. Immunity is crucial for preventing development of toxoplasmic encephalitis (TE) following infection. IFN-gamma-mediated immune response plays a central role in the resistance. The activation of microglia and astrocytes by IFN-gamma or a combination of this cytokine with TNF-alpha appears to be an important effector mechanism in the host immunity. GM-CSF, IL-1 beta and IL-6 may participate in this activation. iNOS is a molecule which mediates the protective activity of the activated murine microglia and human astrocytes; however, another unknown mechanism(s) not mediated by iNOS is involved in the activity of activated murine astrocytes and human microglia. IL-6 plays a protective role, at least in part, by up-regulating IFN-gamma production during the chronic stage of infection in mice. IL-6 also plays a role in regulating the infiltration of T cell subsets into the brain. IL-4 appears to play a protective role, but its role may differ depending on the strains of mice. In contrast to these protective cytokines, IL-10 may play a pathogenic role by down-regulating IFN-gamma production. The resistance against development of TE is under genetic control in both mice and humans. The Ld gene within the D region of the H-2 complex confers resistance in mice. In AIDS patients, HLA-DQ3 appears to be a genetic marker of susceptibility, and HLA-DQ1 appears to be a resistance marker. Strains (genetic variation) of T. gondii is another factor which affects the susceptibility of the host to the development of TE. The genotypes of the parasite may be important for determining the susceptibility. It is possible that the genes of the host and genetic variation of T. gondii affect immune response of the host to the parasite, and thereby contribute to determining the resistance against the development of TE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10631575     DOI: 10.1016/S0171-2985(99)80066-7

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  5 in total

1.  Toxoplasma gondii prevents neuron degeneration by interferon-gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide synthase and transforming growth factor-beta1 production by infected microglia.

Authors:  Claudia Rozenfeld; Rodrigo Martinez; Sérgio Seabra; Celso Sant'anna; J Gabriel R Gonçalves; Marcelo Bozza; Vivaldo Moura-Neto; Wanderley De Souza
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

2.  Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice.

Authors:  Warrison A Andrade; Maria do Carmo Souza; Espiridion Ramos-Martinez; Kamalpreet Nagpal; Miriam S Dutra; Mariane B Melo; Daniella C Bartholomeu; Sankar Ghosh; Douglas T Golenbock; Ricardo T Gazzinelli
Journal:  Cell Host Microbe       Date:  2013-01-03       Impact factor: 21.023

3.  Cytokine and antibody responses of reactivated murine toxoplasmosis upon administration of dexamathasone.

Authors:  Ki-Nam Kang; In-Uk Choi; Dae-Whan Shin; Young-Ha Lee
Journal:  Korean J Parasitol       Date:  2006-09       Impact factor: 1.341

4.  Soluble factors released by Toxoplasma gondii-infected astrocytes down-modulate nitric oxide production by gamma interferon-activated microglia and prevent neuronal degeneration.

Authors:  Claudia Rozenfeld; Rodrigo Martinez; Rodrigo T Figueiredo; Marcelo T Bozza; Flávia R S Lima; Ana Lúcia Pires; Patrícia M Silva; Adriana Bonomo; Joseli Lannes-Vieira; Wanderley De Souza; Vivaldo Moura-Neto
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Analysis of clonal type-specific antibody reactions in Toxoplasma gondii seropositive humans from Germany by peptide-microarray.

Authors:  Pavlo Maksimov; Johannes Zerweck; Aline Maksimov; Andrea Hotop; Uwe Gross; Katrin Spekker; Walter Däubener; Sandra Werdermann; Olaf Niederstrasser; Eckhardt Petri; Marc Mertens; Rainer G Ulrich; Franz J Conraths; Gereon Schares
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.